SEC Form 4 · accession 0001598549-26-000015

Skye Bioscience, Inc. · SKYE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Andrew J. Schwab

Director · 10% Owner

Period of report

Sep 22, 2026

Accepted (ET)

Sep 24, 2026 · 4:31 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001516551

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Sep 22, 2026	S	27,612	$1.65	D	114,851	I	By 5AM Ventures II, L.P.
Common Stock^F2	Sep 22, 2026	S	1,088	$1.65	D	4,528	I	By 5AM Co-Investors II, L.P.
Common Stock^F3,F1	Sep 23, 2026	S	114,851	$1.61	D	0	I	By 5AM Ventures II, L.P.
Common Stock^F3,F2	Sep 23, 2026	S	4,528	$1.61	D	0	I	By 5AM Co-Investors II, L.P.
Common Stock^F4	holding	—	—		—	981,269	I	By 5AM Ventures VII, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F2The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F4The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.